8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole)

8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole)

Salicylate Toxicity: Pathophysiology & Acid-Base Dynamics

Salicylate poisoning (acetylsalicylic acid, aspirin) presents one of the most intellectually rigorous diagnostic and management challenges in clinical emergency toxicology. Salicylates disrupt cellular respiration across multiple organ systems, creating complex mixed acid-base abnormalities.

                      SALICYLATE DUAL ACID-BASE MECHANISM
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. DIRECT MEDULLARY RESPIRATORY CENTER STIMULATION                          │
  │    • Salicylates directly stimulate the brainstem respiratory center        │
  │    • Increases respiratory rate and tidal volume (hyperpnea/tachypnea)       │
  │    • Marked washout of CO2 ──> PRIMARY RESPIRATORY ALKALOSIS                │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. MITOCHONDRIAL UNCOUPLING OF OXIDATIVE PHOSPHORYLATION                    │
  │    • Collapses the electrochemical proton gradient across inner membrane    │
  │    • Halts ATP synthesis; energy is dissipated as heat (HYPERTHERMIA)       │
  │    • Anaerobic glycolysis surges ──> Lactic Acid accumulation               │
  │    • Impairs Krebs cycle dehydrogenases & enhances lipolysis ──> Ketoacids  │
  │    • Net Result ──> PRIMARY HIGH ANION GAP METABOLIC ACIDOSIS               │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ CLASSIC ADULT PRESENTATION: MIXED RESPIRATORY ALKALOSIS & METABOLIC ACIDOSIS│
  └─────────────────────────────────────────────────────────────────────────────┘

The Physics of Ion Trapping & Central Nervous System Penetration

Salicylic acid is a weak monocarboxylic acid with an acid dissociation constant ($pK_a$) of 3.0 to 3.5. In aqueous solution, it exists in an equilibrium between its non-ionized, lipophilic protonated form ($HA$) and its charged, polar conjugate base anion ($A^-$):

$\text{HA} \rightleftharpoons \text{H}^+ + \text{A}^-$

$\text{pH} = pK_a + \log\left(\frac{[A^-]}{[HA]}\right)$

• In Acidemia (Low Blood pH): Le Chatelier's principle dictates that high extracellular hydrogen ion concentrations drive the reaction to the left, increasing the fraction of uncharged, non-ionized salicylic acid ($HA$). Non-ionized molecules readily cross lipid bilayers, including the blood-brain barrier.
• CNS Neuroglycopenia & Cerebral Edema: Once inside neurons, salicylates uncouple oxidative phosphorylation, impairing glucose transport and cellular ATP production. This causes localized neuroglycopenia (intracellular cerebral glucose starvation despite normal systemic serum glucose), cerebral edema, seizures, coma, and herniation.
• In Alkalemia (High Blood pH): Raising the systemic pH shifts the equilibrium toward the charged salicylate anion ($A^-$). Polar ions cannot cross the blood-brain barrier. Systemic alkalinization draws salicylate molecules out of the central nervous system and traps them within the intravascular compartment.

Clinical Presentation

• Early Manifestations: Tinnitus (often the earliest symptom, caused by uncoupling in the microvasculature of the stria vascularis in the inner ear), vertigo, diaphoresis, nausea, vomiting, tachypnea, and hyperpnea.
• Severe Toxicity: Hyperthermia (poor prognostic sign indicating profound mitochondrial uncoupling), agitation, delirium, lethargy, non-cardiogenic pulmonary edema (due to increased pulmonary capillary permeability), acute kidney injury, and cardiovascular collapse.

---

Urinary Alkalinization & Mandatory Potassium Repletion

Urinary alkalinization is the primary emergency department elimination therapy for moderate to severe salicylate poisoning that does not meet hemodialysis criteria.

Mechanism of Enhanced Renal Elimination

Salicylate is freely filtered at the glomerulus and reabsorbed along the proximal and distal convoluted tubules via passive non-ionic diffusion. Under acidic urinary conditions, salicylate remains non-ionized and is passively reabsorbed back into peritubular capillaries. When the urine is alkalinized to a pH of 7.5 to 8.0:

1. Filtered salicylic acid in the tubular lumen is deprotonated into polar salicylate anions ($A^-$).
2. Charged salicylate ions cannot traverse the lipid-rich tubular epithelium.
3. Salicylate is effectively trapped in the lumen and excreted in the urine.
4. Raising urine pH from 5.0 to 8.0 increases renal salicylate clearance by 10- to 20-fold!

Urinary Alkalinization Protocol

• Infusion Composition: 100 to 150 mEq of Sodium Bicarbonate (2 to 3 ampules of 8.4% $\text{NaHCO}_3$) mixed in 1,000 mL of 5% Dextrose in Water (D5W).
• Infusion Rate: Administer at 1.5 to 2 times the maintenance fluid rate (typically 150 to 250 mL/h in adults).
• Target Parameters:
  • Urine pH: Maintain between 7.5 and 8.0 (measure every void or hourly via Foley catheter).
  • Blood / Arterial pH: Maintain between 7.45 and 7.55.
  • Safety Limit: Never permit systemic arterial pH to exceed 7.55 to 7.60. Extreme alkalemia precipitates hypocalcemic tetany, profound hypokalemia, cerebral vasoconstriction, and malignant dysrhythmias.

The Potassium Trap: Mandatory Potassium Repletion

                      THE HYPOKALEMIC PARADOXICAL ACIDURIA TRAP
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ In Hypokalemia:                                                             │
  │   1. Cortical collecting duct alpha-intercalated cells attempt to conserve  │
  │      potassium via the apical H+/K+ ATPase pump                             │
  │   2. To reabsorb one K+ ion, the pump MUST SECRETE ONE H+ ION into urine    │
  │   3. Net Result: PARADOXICAL ACIDURIA (Urine pH < 6.0)                      │
  │   4. Bicarbonate infusion fails to alkalinize tubular fluid; salicylate     │
  │      remains non-ionized and reabsorbs into circulation                     │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ CLINICAL MANDATE: Proactively add 20–40 mEq KCl per liter of bicarbonate    │
  │ infusion to maintain serum potassium at 4.0–4.5 mEq/L.                      │
  └─────────────────────────────────────────────────────────────────────────────┘

---

Indications for Emergent Hemodialysis in Salicylate Toxicity

Salicylates possess ideal physicochemical properties for extracorporeal removal: low molecular weight (138 Da), low volume of distribution ($V_d \approx 0.15–0.2\text{ L/kg}$), and decreased plasma protein binding (which falls from 90% at therapeutic levels to $<50\%$ in severe toxicity). Intermittent hemodialysis rapidly clears salicylate, corrects refractory acid-base disorders, and restores volume equilibrium.

EXTRIP Workgroup Consensus Indications

The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup's 2015 salicylate recommendations do not separate acute from chronic poisoning. Older teaching used a lower threshold (about 60 mg/dL) for chronic toxicity, but EXTRIP relies on concentration, kidney function and clinical features. Intermittent hemodialysis is preferred:

---

Toxic Alcohols: Ethylene Glycol vs. Methanol

Ingestion of toxic alcohols constitutes an immediate, life-threatening metabolic emergency. While parent alcohols produce modest inebriation, their oxidized hepatic metabolites generate devastating systemic toxicity.

                           TOXIC ALCOHOL METABOLISM
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ ETHYLENE GLYCOL:                                                            │
  │   Ethylene Glycol ──(Alcohol Dehydrogenase)──> Glycoaldehyde                │
  │   Glycoaldehyde ──(Aldehyde Dehydrogenase)───> Glycolic Acid (Acidosis)     │
  │   Glycolic Acid ─────────────────────────────> Glyoxylic Acid               │
  │   Glyoxylic Acid ──(Thiamine/Pyridoxine)─────> α-Hydroxy-ketoadipate/Glycine│
  │   Glyoxylic Acid ──(Oxidation)───────────────> Oxalic Acid                  │
  │       └─> Binds Ca2+ ──> Calcium Oxalate Monohydrate Crystals (AKI & ATN)   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ METHANOL:                                                                   │
  │   Methanol ──(Alcohol Dehydrogenase)─────────> Formaldehyde                 │
  │   Formaldehyde ──(Aldehyde Dehydrogenase)────> Formic Acid (Formate)        │
  │   Formic Acid ──(Folate / Leucovorin Pathway)─> CO2 + H2O                   │
  │       └─> Inhibits Cytochrome Oxidase ───────> Optic Neuritis / Blindness,  │
  │                                                Basal Ganglia / Putaminal Nec│
  └─────────────────────────────────────────────────────────────────────────────┘

Toxic Alcohol Comparison Matrix

Osmolar Gap & Anion Gap Dynamics

• Calculated Serum Osmolarity: $\text{Calculated Osmolarity} = 2[\text{Na}^+] + \frac{[\text{Glucose}]}{18} + \frac{[\text{BUN}]}{2.8} + \frac{[\text{Ethanol}]}{4.6}$
• Osmolar Gap: $\text{Osmolar Gap} = \text{Measured Osmolality (Freezing Point)} - \text{Calculated Osmolarity}$
• The Diagnostic Gap Timeline: A normal osmolar gap is $<10\text{ mOsm/kg}$. An osmolar gap $>20\text{ mOsm/kg}$ strongly suggests the presence of an unmeasured toxic alcohol.
  • Early Post-Ingestion: Parent alcohols are low-molecular-weight, osmotically active particles. Initially, the osmolar gap is markedly elevated, while the anion gap is completely normal.
  • Late Post-Ingestion: As alcohol dehydrogenase metabolizes parent molecules into charged organic acids (glycolate or formate), the osmolar gap closes while the high anion gap metabolic acidosis widens.

Antidote Therapy: Fomepizole vs. Ethanol

Definitive antidote therapy for toxic alcohol ingestion centers on blocking the initial rate-limiting enzyme: Alcohol Dehydrogenase (ADH).

Fomepizole (4-Methylpyrazole, 4-MP)

Fomepizole is the preferred, first-line antidote for both ethylene glycol and methanol poisonings.

• Mechanism: Potent competitive inhibitor of ADH with an affinity for the enzyme approximately 8,000 times greater than that of ethanol.
• Standard Dosing Regimen:
  • Loading Dose: 15 mg/kg IV administered as an infusion over 30 minutes.
  • Maintenance Dosing: 10 mg/kg IV every 12 hours for 4 doses.
  • Auto-induction Adjustment: After 48 hours of continuous therapy, fomepizole induces its own hepatic CYP450 metabolism; the maintenance dose must be increased to 15 mg/kg IV every 12 hours until toxic alcohol levels clear.
• Hemodialysis Dosing Adjustment: Fomepizole is a small molecule that is cleared by hemodialysis. During intermittent hemodialysis, the dosing interval must be shortened to every 4 hours, or administered as a continuous infusion of 1 to 1.5 mg/kg/hour.
• Discontinuation Endpoints: Continue fomepizole until the ethylene glycol or methanol concentration is $<20–30\text{ mg/dL}$, the anion gap normalizes, and systemic acid-base balance is restored.

Ethanol Therapy (Second-Line Alternative)

When fomepizole is unavailable, pharmaceutical-grade intravenous or oral ethanol can be utilized:

• Mechanism: Competes with toxic alcohols for ADH; ADH exhibits approximately 10-fold higher affinity for ethanol than for ethylene glycol or methanol.
• Target Blood Level: Maintain blood ethanol concentration at 100 to 150 mg/dL (22 to 33 mmol/L).
• Complications: Intravenous ethanol therapy is notoriously hazardous, requiring complex loading and maintenance calculations, frequent blood glucose and ethanol monitoring, and carries severe risks of central nervous system depression, respiratory arrest, phlebitis, and catastrophic hypoglycemia (especially in pediatric patients due to inhibition of gluconeogenesis).

---

Adjunctive Metabolic Cofactor Therapy

Cofactors do not inhibit ADH; rather, they drive alternative, non-toxic metabolic pathways to accelerate the elimination of downstream metabolites:

1. Methanol Cofactors

• Leucovorin (Folinic Acid) or Folic Acid: 50 mg IV every 4 hours.
• Mechanism: Formic acid is metabolized by the enzyme 10-formyl tetrahydrofolate dehydrogenase. Folate cofactors enhance the tetrahydrofolate pathway, accelerating the conversion of toxic formic acid into non-toxic carbon dioxide and water.

2. Ethylene Glycol Cofactors

• Thiamine (Vitamin B1): 100 mg IV every 6 hours.
  • Mechanism: Acts as a vital cofactor with the enzyme alpha-hydroxy-beta-ketoadipate synthase to convert glyoxylic acid into non-toxic alpha-hydroxy-beta-ketoadipate.
• Pyridoxine (Vitamin B6): 50 mg IV every 6 hours.
  • Mechanism: Acts as a transaminase cofactor converting glyoxylic acid into the non-toxic amino acid glycine.
• Synergy: Together, thiamine and pyridoxine divert glyoxylic acid away from oxalic acid formation, directly mitigating calcium oxalate crystal deposition in the renal parenchyma.